Please assess the completion status of the following clinical trial:

Trial Title: VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with no medical, psychiatric or current sleep disorders.~* Subject must sign a written consent form.~Exclusion Criteria:~* Recent history of night shift work or jet lag.~* Prior experience sleeping in a sleep lab environment.~* History of sleep disorders.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Take orally 30 minutes prior to bedtime.
- 20 mg VEC-162 (Type: EXPERIMENTAL): 20 mg taken orally 30 minutes prior to bedtime.
- 50 mg VEC-162 (Type: EXPERIMENTAL): 50 mg taken orally 30 minutes prior to bedtime.
- 100 mg VEC-162 (Type: EXPERIMENTAL): 100 mg taken orally 30 minutes prior to bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).